Brought to you by 
Amicus, UPenn ally to develop rare disease gene therapies
02 Jul 2019
Executive Summary
Amicus Therapeutics Inc. is teaming up with the University of Pennsylvania to research and develop adeno associated virus (AAV) gene therapies for Pompe disease, Fabry disease, CDKL5 deficiency (seizures), and one undisclosed rare metabolic disorder.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Amicus, UPenn ally to develop rare disease gene therapies
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice